PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18341691-11	2008	The binding of nuclear proteins to oligonucleotides encoding the putative cd38 NF-kappaB site and some of the six AP-1 sites was increased by TNF-alpha, and to some of the putative cd38 GREs by dexamethasone.	Dexamethasone	194-207	CD38 molecule	Homo sapiens	181-185	
18441094-8	2008	Dexamethasone also decreased CD38 expression induced by TNF-alpha, and part of this effect was attributable to decreased transcript stability.	Dexamethasone	0-13	CD38 molecule	Homo sapiens	29-33	
18441094-9	2008	In cells transfected with MKP-1-specific small interfering RNAs (siRNAs), there was significant attenuation of MKP-1 expression and partial, but nonsignificant, reversal of dexamethasone inhibition of CD38 expression.	Dexamethasone	173-186	CD38 molecule	Homo sapiens	201-205	
18341691-0	2008	Regulation of the cd38 promoter in human airway smooth muscle cells by TNF-alpha and dexamethasone.	Dexamethasone	85-98	CD38 molecule	Homo sapiens	18-22	
18341691-11	2008	The binding of nuclear proteins to oligonucleotides encoding the putative cd38 NF-kappaB site and some of the six AP-1 sites was increased by TNF-alpha, and to some of the putative cd38 GREs by dexamethasone.	Dexamethasone	194-207	CD38 molecule	Homo sapiens	74-78	
16571778-9	2006	The results indicate that TNF-alpha-induced CD38 expression involves NF-kappaB expression and its activation and dexamethasone inhibits CD38 expression through NF-kappaB-dependent and -independent mechanisms.	Dexamethasone	113-126	CD38 molecule	Homo sapiens	136-140	
16571778-4	2006	In the present study, we investigated the effects of dexamethasone, a glucocorticoid, on CD38 expression and ADP-ribosyl cyclase activity in HASM cells stimulated with TNF-alpha.	Dexamethasone	53-66	CD38 molecule	Homo sapiens	89-93	
16571778-5	2006	In HASM cells, TNF-alpha augmented CD38 expression and ADP-ribosyl cyclase activity, which were attenuated by dexamethasone.	Dexamethasone	110-123	CD38 molecule	Homo sapiens	35-39	
33275735-2	2020	Currently, there are 3 CD38 antibody-based regimens approved for the treatment of both transplant-eligible (daratumumab plus bortezomib-thalidomide-dexamethasone [D-VTd]) and transplant-ineligible (daratumumab plus lenalidomide-dexamethasone [D-Rd] or daratumumab plus bortezomib-melphalan-prednisone [D-VMP]) patients with newly diagnosed MM (NDMM).	Dexamethasone	148-161	CD38 molecule	Homo sapiens	23-27	
16291871-3	2006	We found that CD38 expression induced by TNFalpha alone was completely abrogated by fluticasone (100 nM), dexamethasone (1 microM), or budesonide (100 nM).	Dexamethasone	106-119	CD38 molecule	Homo sapiens	14-18	
34521277-1	2021	In the Phase III ICARIA-MM study (NCT02990338), the addition of the anti-CD38 monoclonal antibody isatuximab to pomalidomide and dexamethasone led to increased progression-free survival and improved response rates in patients with relapsed/refractory multiple myeloma.	Dexamethasone	129-142	CD38 molecule	Homo sapiens	73-77	
33714285-6	2021	We found that ibrutinib combined with DXMS increased the apoptosis of MM cell lines through the PI3K/PARP pathway, significantly reduced CD38 expression in MM cells from patients in vitro, and reduced tumor size and increased the survival time in mice model.	Dexamethasone	38-42	CD38 molecule	Homo sapiens	137-141	
33260960-4	2020	More recently, another anti-CD38 MoAb named isatuximab was approved by FDA in combination with pomalidomide-dexamethasone (Pd) in the same setting.	Dexamethasone	108-121	CD38 molecule	Homo sapiens	28-32	
32435618-6	2020	Among the novel anti-myeloma IT-based agents, anti-CD38 monoclonal antibodies (mAbs) are now becoming the new backbone of treatment for NTE patients, in association with lenalidomide and dexamethasone.	Dexamethasone	187-200	CD38 molecule	Homo sapiens	51-55	
30079070-1	2018	Monoclonal antibodies against the cell surface antigen CD38, e.g., isatuximab, daratumumab, or Mor202, have entered the therapeutic armamentarium in multiple myeloma due to single agent overall response rates of 29 vs. 36 vs. 31%, effectivity in combination regimen, e.g., with lenalidomide or bortezomib plus dexamethasone, and tolerable side effects.	Dexamethasone	310-323	CD38 molecule	Homo sapiens	55-59	
27611189-7	2016	Furthermore, anti-CD38-IFNalpha(attenuated) is more efficacious than standard MM treatments (lenalidomide, bortezomib, dexamethasone) and exhibits strong synergy with lenalidomide and with bortezomib in xenograft models.	Dexamethasone	119-132	CD38 molecule	Homo sapiens	18-22